title: Efficacy of intravenous propranolol for suppression of inducibility of ventricular tachyarrhythmias with different electrophysiologic characteristics in coronary artery disease.
abstract: The efficacy of intravenous propranolol for suppression of inducibility of sustained ventricular tachyarrhythmias (VT) was studied in 24 patients who had failed greater than or equal to 1 membrane-active antiarrhythmic drug (mean 2.2 +/- 1.2 drugs/patient). The response to propranolol was compared in 13 patients who had only stable monomorphic VTs inducible at baseline and another 11 patients who had greater than or equal to 1 episode of electrically unstable VTs (polymorphic VT, ventricular flutter or ventricular fibrillation) at baseline. Seven patients (29%) became noninducible (responders) and 17 patients (71%) remained inducible to sustained VT (nonresponders) after propranolol. The basal heart rate was faster in responders than in nonresponders (101 +/- 14 vs 86 +/- 11 beats/min, p less than 0.01). The magnitude of heart rate reduction was also greater after propranolol in responders (from 101 +/- 14 to 80 +/- 9 beats/min, p less than 0.001) than in nonresponders (from 86 +/- 11 to 74 +/- 9 beats/min, p less than 0.01) (p less than 0.05 between the groups), despite equal plasma propranolol concentrations (84 +/- 50 vs 88 +/- 43 ng/ml, difference not significant). Seven of 11 patients (64%) who had greater than or equal to 1 episode of unstable VTs inducible at baseline responded to intravenous propranolol, whereas none of the patients with only stable monomorphic VTs became noninducible after beta blockade (p less than 0.001). Responders had shorter cycle length of inducible VTs than nonresponders (225 +/- 38 vs 302 +/- 66 ms, p less than 0.001). Thus, intravenous propranolol appears to be efficacious in suppressing fast, electrically unstable VTs, compared to monomorphic VTs with slower rates.
authors.affiliation: Division of Cardiology, University of Miami Medical School, Florida.
authors.forename: H V
authors.initials: HV
authors.lastname: Huikuri
authors.forename: M
authors.initials: M
authors.lastname: Cox
authors.forename: A
authors.initials: A
authors.lastname: Interian
authors.forename: K M
authors.initials: KM
authors.lastname: Kessler
authors.forename: F
authors.initials: F
authors.lastname: Glicksman
authors.forename: A
authors.initials: A
authors.lastname: Castellanos
authors.forename: R J
authors.initials: RJ
authors.lastname: Myerburg
mesh_terms: D000368:Aged; D003327:Coronary Disease / Q000150:complications*; D004594:Electrophysiology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D011433:Propranolol